AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04925635 — intervention group
Intervention type: BEHAVIORAL
Intervention: experimental group
Description: The arteriovenous fistula care mobile health application will be installed and promoted on the smart phones of the patients in the experimental group. Arteriovenous fistula care mobile health application will be installed in daytime groups during working hours during or at the end of dialysis according to the patient's request. In addition, the information contained in the arteriovenous care mobile health application will be verbally explained to the patients and their relatives, as well as shown in practice. The training results were evaluated by the researcher in the 1st and 3rd months in the Scale for Evaluation of Self-Care Behaviors Related to Arteriovenous Fistula in Hemodialysis Patients, Final Level of Renal Failure Compliance Scale, Arteriovenous Fistula Care Education Knowledge Level Evaluation Form (Post-Training Section) and  Visual Benchmarking Scale .
Study NCT04925635 — intervention group
Intervention type: BEHAVIORAL
Intervention: control group
Description: Patients in the control group will receive arteriovenous fistula care training and a training booklet will be given. The information contained in the booklet will be explained orally to the patients and their relatives by the researcher, and will also be shown in practice. The results of the training were determined by the researcher at the 1st and 3rd months of the Self-Care Behaviors Scale for Arteriovenous Fistula in Hemodialysis Patients, End Stage Renal Failure Compliance Scale, Arteriovenous Fistula Care Training Information Level Assessment Form (Post-training section) and Visual It will be evaluated with the Comparison Scale.
Study NCT02530385 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: Placebo capsules contain powdered cocoa and gelatin
Study NCT02530385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT Capsules
Description: Capsules will be generated as per FDA-approved procedures
Study NCT02217579 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein plus prebiotic fiber
Description: A food containing supplemental protein (5 grams/serving) and prebiotic fiber (8 grams/serving).
Study NCT02217579 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: An isocaloric food not containing the test protein and fiber.
Study NCT00143676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and atorvastatin
Description: Lapaquistat acetate 50 mg, tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
Study NCT00143676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate and atorvastatin
Description: Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
Study NCT00143676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
Study NCT02092688 — intervention group
Intervention type: DEVICE
Intervention: novel kit for the detection of PAMG-1
Description: The novel kit for the detection of PAMG-1 is a diagnostic device employing monoclonal antibodies that detect Placental α1 Microglobulin present in cervico-vaginal secretions manufactured by AmniSure® International, LLC, Boston, MA. The in vivo sensitivity detection threshold is 4ng/ml. During the test procedure, PAMG-1 from the sample sequentially binds to monoclonal antibody conjugated with labeled particles, then to monoclonal antibody immobilized on an insoluble carrier. The test requires a 30 second swab saturation in the vagina (a sterile speculum examination is not required), a 30 second active washing step whereby the swab just removed from the vagina is actively rotated in a solvent filled vial and lastly, a 5 minute waiting period from the time the swab is removed and the test strip is inserted if two testing lines do not appear sooner.
Study NCT05028907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg chloramphenicol, 1 mg dexamethasone sodium phosphate, 0.25 mg tetryzoline hydrochloride, 2 mg Hydroxypropyl Methyl Cellulose, 10 mg α-tocopherol acetate and 8 mg macrogol 400).
Description: The patients were advised to apply the drops 5 times daily for the first week, three times daily for the next two weeks and one time daily for another one week. The patients were examined before treatment, one week, one month and three months later.
Study NCT00318396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone preparation technique: compaction
Description: The bone is pressed very hard together before implantation of femoral component.
Study NCT05028907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium hyaluronate, polyethylene and propylene glycol based) three times daily for three months
Description: The patients were advised to apply the drops 5 times daily for the first week, three times daily for the next two weeks and one time daily for another one week. The patients were examined before treatment, one week, one month and three months later.
Study NCT00318396 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone preparation technique: conventional technique
Description: Bone is broached before implantation of femoral component.
Study NCT03722576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vidofludimus calcium
Description: During the 6-month treatment period, subjects will receive 30 mg VC orally once daily. This will be preceded by a lead-in dosing period where subjects will receive 15 mg VC once daily for 1 week.
Study NCT02130440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol nasal spray
Study NCT02130440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol nasal spray
Study NCT00062179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Celecoxib: 400 mg po BID celecoxib 3-7 days before first dose of chemotherapy
Study NCT00062179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion 3 cycles of paclitaxel 21 days apart
Study NCT00062179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion 3 cycles of paclitaxel 21 days apart
Study NCT00062179 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 3-7 days before first dose of chemotherapy
Study NCT03353844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise
Description: intradialytic exercise which start and finish in first hour of hemodiafiltration session
Study NCT02864030 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ERIBULIN MESYLATE
Description: Eribulin mesylate will be administered according to the European Medicines Agency (EMA) and Italian Medicines Agency (AIFA) approved indications and schedule consists in 1.23 mg/m2 on day 1 and on day 8 of each cycle. Cycles will be repeated every 21 days until progression of disease, unacceptable toxicity, patient refusal or medical decision.~The decision to treat patients with Eribulin is independent from the trial. Patients will be treated and managed according to clinical practice. The physician can choose any further line of treatment after disease progression with Eribulin.
Study NCT03599609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: Simvastatin 40mg, once daily
Study NCT03705832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginger Extract
Description: 2gm Capsule of Ginger extract
Study NCT03705832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT00116142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg/m² q 3 weeks for 3 cycle at the start of treatment followed by weekly Docetaxel at 20 mg/m² per week beginning at week one of radiation therapy and continuing for seven weeks.
Study NCT00116142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Hormonal Suppression and Radiation
Description: Total Androgen Ablation and external beam radiation therapy
Study NCT00116142 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Androgen Hormonal Suppression and Radiation
Description: Total Androgen Ablation and external beam radiation therapy
Study NCT00116142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Suppression Therapy and Radiation Therapy
Description: Total Androgen Ablation and External Beam Radiation Therapy
Study NCT00116142 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Androgen Suppression Therapy and Radiation Therapy
Description: Total Androgen Ablation and External Beam Radiation Therapy
Study NCT03582683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Pain Self-Management Program (CPSMP)
Description: Stanford University's Chronic Pain Self-Management Program (CPSMP) was developed by Sandra LeFort in 1996 and based on Stanford's Arthritis Self-Management Program and the Chronic Disease Self-Management Program. The 6-week community-delivered workshop consists of 2.5-hour weekly sessions for people with a primary or secondary diagnosis of Chronic Pain.
Study NCT03582683 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Pain Self-Management Program (CPSMP)
Description: Stanford University's Chronic Pain Self-Management Program (CPSMP) was developed by Sandra LeFort in 1996 and based on Stanford's Arthritis Self-Management Program and the Chronic Disease Self-Management Program. The 6-week community-delivered workshop consists of 2.5-hour weekly sessions for people with a primary or secondary diagnosis of Chronic Pain.
Study NCT04506736 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ARM
Description: The ARM is performed by setting the peak inspiratory pressure to 45 cmH₂O then changing the mode of ventilation to pressure controlled ventilation (PCV) with the inspiratory pressure set to give a tidal volume equal to that given during VCV, I:E ratio of 1:1 and a PEEP of 5 cmH₂O. The PEEP level is then increased in 5 cmH₂O steps every minute till it reaches 20 cmH₂O and inspiratory pressure is increased to get an airway opening pressure (inspiratory pressure + PEEP) of 40 cmH₂O which is maintained for one minute after which the ventilation returned to the original setting except for the PEEP level which is kept at 20 cmH₂O.~The titration of individualized PEEP is done by decremental reduction of the 20 cmH₂O PEEP level in 2 cmH₂O steps every 2 minutes and measuring static compliance of the respiratory system (CRS) at each step.
Study NCT04506736 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spontanous ventilation
Description: volume controlled ventilation (7ml/kg tidal volume) with addition of 5 cm H₂O fixed PEEP till the end of the surgery .
Study NCT01720966 — intervention group
Intervention type: PROCEDURE
Intervention: Liver resection
Description: Liver resection performed for metastatic disease from colorectal carcinoma
Study NCT01694134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortancyl.
Description: Patients will receive an intradiscal injection of hydrocortancyl.
Study NCT01694134 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lidocaine
Study NCT01384656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GIK solution
Description: Patients receive 0.3 ml/kg/hr GIK solution or the same volume of normal saline depending on the group during off-pump coronary bypass surgery. GIK solution consist of 50% glucose, potassium 80 mEq, and regular insulin 325 IU/500ml.
Study NCT01384656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIK solution
Description: Patients receive 0.3 ml/kg/hr GIK solution or the same volume of normal saline depending on the group during off-pump coronary bypass surgery. GIK solution consist of 50% glucose, potassium 80 mEq, and regular insulin 325 IU/500ml.
Study NCT01259245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai chi + PRP
Description: The exercise content was totally identical to PRP group except 15 minutes of 5 Sun Style Tai Chi were substituted to 15 minutes of relaxation exercise
Study NCT01259245 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: Formal pulmonary rehabilitation program consisted of overview of COPD management, aerobic exercises, breathing control exercises, Thera-Band strengthening exercises, safety precautions for physical training and goal setting
Study NCT01259245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP
Description: Formal pulmonary rehabilitation program consisted of overview of COPD management, aerobic exercises, breathing control exercises, Thera-Band strengthening exercises, safety precautions for physical training and goal setting
Study NCT02477124 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transvaginal digital colposcope (TVDC)
Description: TVDC is a miniature colposcope used to obtain images of cervical tissue.
Study NCT02477124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care screening
Description: Standard of care screening varies from institution to institution but is either visual inspection with the naked eye, colposcopy, or visual inspection with a camera or microscope
Study NCT00496015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A.
Description: 1 intramuscular injection.
Study NCT00496015 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa.
Description: 1 intramuscular injection.
Study NCT00496015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa.
Description: 1 intramuscular injection.
Study NCT00496015 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal vaccine GSK134612.
Description: 1 intramuscular injection.
Study NCT00496015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol.
Description: Body weight of \< 7 kg: none; Body weight of ≥ 7 kg to \< 9 kg : 3 suppositories of 125 mg to be administered at 8h intervals after vaccination. Body weight of ≥ 9 kg: 4 suppositories of 125 mg to be administered at 6h intervals after vaccination.
Study NCT01116401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide
Description: Leuprolide acetate is a widely used GnRH agonist. In this protocol, leuprolide will be administered at a dose routinely used for treatment of endometriosis and uterine fibroids in women (one 3.75-mg intramuscular injection).
Study NCT01535807 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CorMatrix extra cellular matrix (ECM)
Description: * Cormatrix ECM group will receive the CorMatrix ECM during surgery for the closure of the pericardium according to the specific recommended surgical technique.~* No Intervention group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care.
Study NCT03498807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventiltor P/V Loop
Description: determine the Optimal PEEP and keep 48hr on ARDS patients
Study NCT03498807 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Impedance Tomography
Description: determine Optimal PEEP and keep 48hr on ARDS patients
Study NCT02451917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine insulin
Description: The initial insulin dose for those randomized to IGlar was 80% of the total daily NPH dose that was being discontinued. All of them had pre-prandial Regular insulin switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. After 24 weeks, basal insulins were switched; in other words, individuals on IGlar in the first period switched to INPH, and the doses of pre-meal insulin were sustained
Study NCT02451917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Description: The same total daily NPH insulin dose was maintained for those randomized to INPH. All of them had pre-prandial Regular insulin (Humulin R™, Lilly, Brazil) switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. . After 24 weeks, basal insulins were switched; in other words, individuals on NPH in the first period switched to glargine insulin, and the doses of pre-meal insulin were sustained.
Study NCT00228358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ex vivo-expanded HER2-specific T cells
Description: Laboratory-expanded T cells, given IV
Study NCT00228358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00228358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denileukin diftitox
Description: Given IV
Study NCT00228358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Intracellular cytokine staining (correlative study)
Study NCT00228358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: ELIspot assay (correlative study)
Study NCT01316874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valrubicin, 800 mg
Description: Investigator will be responsible for regulating the use of concomitant medications (systemic and/or topical anticholinergic therapy or topical anesthesia) and other medications.
Study NCT03833726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: LED group
Description: 5 Sessions of 8 minute 405 nm Blue Light Emitting Diode, LED, with a power of 1.66 W / m2, 7 days apart.
Study NCT03833726 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Control
Description: 5 Sessions of 8 minute with device off and heated gel, 7 days apart.
Study NCT01768507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol
Description: 5 g (10 capsules) as single oral dose on day 1
Study NCT01768507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 5 g (10 capsules) as single oral dose on day 1
Study NCT03708107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEP
Description: MEP® will be applied with an acupuncture needle (0,30 x 25 mm). The needle will be introduced perpendicularly to the MTrP with 100 uA and then increased up to 600 uA. The current will be paused if the patient feels a burning sensation, pain or oppression, waiting up to the patient feels no discomfort. The procedure will be repeated as many times is necessary until the patient do not feel any discomfort for more than 1 minute.
Study NCT03708107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic compression
Description: Ischemic compression will be applied perpendicularly to the MTrP, increasing gradually the pression until the patient refers the maximum tolerable pain. This pressure will be applied for 1 minute.
Study NCT03255135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU
Description: High intensity focused ultrasound prostate cancer therapy guided by biopsy specimens and multiparametric prostate magnetic resonance using Focal One, Edap TMS, France device.
Study NCT03071068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PlGF recombinant monoclonal antibody, 4mg dose
Description: 3 intravitreal injections of THR-317 4mg approximately 1 month apart
Study NCT03071068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PlGF recombinant monoclonal antibody, 8mg dose
Description: 3 intravitreal injections of THR-317 8mg approximately 1 month apart
Study NCT04058041 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neural Mobilization
Description: neural exercise Will be performed in the patients
Study NCT04058041 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: open or endoscopic surgery will be permed in the patients with tunnel carpal syndrome
Study NCT04058041 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: open or endoscopic surgery will be permed in the patients with tunnel carpal syndrome
Study NCT04058041 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery and neural mobilization
Description: following the surgery patients will be treat with neural mobilization exercises.
Study NCT04058041 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery and neural mobilization
Description: following the surgery patients will be treat with neural mobilization exercises.
Study NCT02599363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib (LEE011)
Study NCT02599363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT03471247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-Bed Cycle Ergometer
Description: Physiotherapists will place the patient's legs in a specialized in-bed cycle ergometer allowing for gentle leg exercise. Exercise can performed in passive, active-assisted, or active mode.
Study NCT03471247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine PT
Description: Includes, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out- of bed mobility, ambulation, and assistance with optimizing airway clearance and respiratory function.
Study NCT03471247 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine PT
Description: Includes, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out- of bed mobility, ambulation, and assistance with optimizing airway clearance and respiratory function.